乳がん薬の世界市場展望2017-20276

◆英語タイトル:Breast Cancer Drug - Global Market Outlook (2017-2026)
◆商品コード:SMRC20FB349
◆発行会社(リサーチ会社):Stratistics MRC
◆発行日:2019年7月
◆ページ数:154
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥456,500見積依頼/購入/質問フォーム
Five UserUSD5,250 ⇒換算¥577,500見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Stratistics MRC社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Stratistics MRCは世界の乳がん薬市場が2017年147.5憶ドルから2026年432.7憶ドルまで年平均12.7%成長すると予測しています。当資料では乳がん薬について調査を行い、エグゼクティブサマリー、序論、市場トレンド分析、ファイブフォース分析、種類別(有糸分裂阻害剤、アロマターゼ阻害剤、ホルモンレック、HER2阻害剤、代謝産物)分析、薬別(標的療法薬、化学療法薬、ホルモン療法薬、その他)分析、流通経路別(クリニック、オンライン薬局、外来手術センター、病院、小売薬局)分析、地域別分析、主要動向、企業概要に区分し掲載しています。
・エグゼクティブサマリー
・序論
・市場トレンド分析
・ファイブフォース分析
・乳がん薬の世界市場:種類別(有糸分裂阻害剤、アロマターゼ阻害剤、ホルモンレック、HER2阻害剤、代謝産物)
・乳がん薬の世界市場:薬別(標的療法薬、化学療法薬、ホルモン療法薬、その他)
・乳がん薬の世界市場:流通経路別(クリニック、オンライン薬局、外来手術センター、病院、小売薬局)
・乳がん薬の世界市場:地域別
・主要動向
・企業概要
【レポートの概要】

According to Stratistics MRC, the Global Breast Cancer Drug Market is accounted for $14.75 billion in 2017 and is expected to reach $43.27 billion by 2026 growing at a CAGR of 12.7% during the forecast period. High prevalence of breast cancer, growing R&D investments and rising healthcare expenditure and awareness are some of the key factors influence market growth. However, stringent regulatory guidelines and expiry of patented drugs is restraining the market growth.

Breast cancer is most commonly diagnosed cancer in women worldwide and also is one of the leading causes of death. Breast cancer is a disease where uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Breast cancer is the result of uncontrolled cell division of breast cells, most commonly cells of breast lobule and ducts.

Based on Drug, Chemotherapy Drugs segment growth is due to development in the fields of drug delivery and oncology, and increased government funding and initiative to create awareness about cancer diagnosis and treatment. By Geography, North America is going to have a lucrative growth due to prevalence of chronic diseases, growing focus of global pharmaceutical companies in this region.

Some of the key players profiled in the Breast cancer drug Market include Novartis AG, Celgene Corporation, Janssen Global Services LLC, Onyx Pharmaceuticals Inc., AbbVie, Inc., Eli Lilly and Company, Celldex Therapeutics, BioNumerik Pharmaceuticals, Inc., AstraZeneca, Merck & Co., Inc., Genzyme Corporation, MacroGenics, Inc., F. Hoffmann-La Roche Ltd. and Biocon.

Procedures Covered:
• Mitotic inhibitor
• Aromatase inhibitor
• Hormonal rec
• HER2 inhibitor
• Anti-metabolites
• CDK 4/6 inhibitor

Drugs Covered:
• Targeted Therapy Drugs
• Chemotherapy Drugs
• Hormone Therapy Drugs
• Other Drugs

Drugs Covered:
• Clinics
• Online Pharmacies
• Ambulatory Surgical centers
• Hospitals
• Retail Pharmacies

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

【レポートの目次】

1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Futuristic Market Scenario
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Breast Cancer Drug Market, By Type
5.1 Introduction
5.2 Mitotic Inhibitor
5.3 Aromatase Inhibitor
5.4 Hormonal rec
5.5 HER2 Inhibitor
5.6 Anti-Metabolites
5.7 CDK 4/6 Inhibitor
6 Global Breast Cancer Drug Market, By Drug
6.1 Introduction
6.2 Targeted Therapy Drugs
6.2.1 Ado-Trastuzumab Emtansine
6.2.2 Neratinib
6.2.3 Monoclonal Antibodies (mAbs)
6.2.3.1 Bevacizumab
6.2.3.2 Trastuzumab
6.2.3.3 Other Monoclonal Antibodies (mAbs)
6.2.4 Lapatinib
6.2.5 Tyrosine kinase inhibitors
6.3 Chemotherapy Drugs
6.3.1 Antimetabolites
6.3.1.1 Capecitabine
6.3.1.2 Gemcitabine
6.3.1.3 Fluorouracil
6.3.2 Anthracyclines
6.3.2.1 Epirubicin
6.3.2.2 Doxorubicin
6.3.3 Alkylating Agents
6.3.4 Neoadjuvant Chemotherapy
6.3.5 Adjuvant Chemotherapy
6.3.6 Taxanes
6.3.6.1 Docetaxel
6.3.6.2 Paclitaxel
6.3.7 Advanced Breast Cancer
6.3.8 Epothilones
6.4 Hormone Therapy Drugs
6.4.1 Ecstasy and Related Drug (ERD)
6.4.2 Selective Estrogen-Receptor Modulators (SERMs)
6.4.2.1 Tamoxifen
6.4.2.2 Toremifene
6.4.2.3 Raloxifene
6.4.3 Aromatase Inhibitors
6.4.3.1 Anastrozole
6.4.3.2 Letrozole
6.4.3.3 Megestrol
6.4.5 Luteinising Hormone-Releasing Hormone
6.4.6 Other Hormonal Therapies
6.4.6.1 Goserelin Acetate
6.4.6.2 Fulvestrant
6.4.6.3 Fluoxymesterone
6.5 Other Drugs
7 Global Breast Cancer Drug Market, By Distribution Channel
7.1 Introduction
7.2 Clinics
7.3 Online Pharmacies
7.4 Ambulatory Surgical Centers
7.5 Hospitals
7.6 Retail Pharmacies
8 Global Breast Cancer Drug Market, By Drug
8.1 North America
8.1.1 US
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 France
8.2.3 Italy
8.2.4 UK
8.2.5 Spain
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Australia
8.3.5 New Zealand
8.3.6 Rest of Asia Pacific
8.4 South America
8.4.1 Argentina
8.4.2 Brazil
8.4.3 Venezuela
8.4.4 Chile
8.4.5 Peru
8.5 Middle East & Africa
8.5.1 UAE
8.5.2 Saudi Arabia
8.5.3 Qatar
8.5.4 Iran
8.5.5 South Africa
8.5.6 Rest of MEA
9 Vendor Landscaping
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiles
10.1 Novartis AG
10.2 Celgene Corporation
10.3 Janssen Global Services LLC
10.4 Onyx Pharmaceuticals Inc.
10.5 AbbVie, Inc.
10.6 Eli Lilly and Company
10.7 Celldex Therapeutics
10.8 BioNumerik Pharmaceuticals, Inc.
10.9 AstraZeneca
10.10 Merck & Co., Inc.
10.11 Genzyme Corporation
10.12 MacroGenics, Inc.
10.13 F. Hoffmann-La Roche Ltd.
10.14 Biocon
List of Tables
Table 1 Global Breast Cancer Drug Market Outlook, By Region (2016-2026)(US $MN)
Table 2 Global Breast Cancer Drug Market Outlook, By Type (2016-2026)(US $MN)
Table 3 Global Breast Cancer Drug Market Outlook, By Mitotic Inhibitor (2016-2026)(US $MN)
Table 4 Global Breast Cancer Drug Market Outlook, By Aromatase Inhibitor (2016-2026)(US $MN)
Table 5 Global Breast Cancer Drug Market Outlook, By Hormonal rec (2016-2026)(US $MN)
Table 6 Global Breast Cancer Drug Market Outlook, By HER2 Inhibitor (2016-2026)(US $MN)
Table 7 Global Breast Cancer Drug Market Outlook, By Anti-Metabolites (2016-2026)(US $MN)
Table 8 Global Breast Cancer Drug Market Outlook, By CDK 4/6 Inhibitor (2016-2026)(US $MN)
Table 9 Global Breast Cancer Drug Market Outlook, By Drug (2016-2026)(US $MN)
Table 10 Global Breast Cancer Drug Market Outlook, By Targeted Therapy Drugs (2016-2026)(US $MN)
Table 11 Global Breast Cancer Drug Market Outlook, By Ado-Trastuzumab Emtansine (2016-2026)(US $MN)
Table 12 Global Breast Cancer Drug Market Outlook, By Neratinib (2016-2026)(US $MN)
Table 13 Global Breast Cancer Drug Market Outlook, By Monoclonal Antibodies (mAbs) (2016-2026)(US $MN)
Table 14 Global Breast Cancer Drug Market Outlook, By Lapatinib (2016-2026)(US $MN)
Table 15 Global Breast Cancer Drug Market Outlook, By Tyrosine kinase inhibitors (2016-2026)(US $MN)
Table 16 Global Breast Cancer Drug Market Outlook, By Chemotherapy Drugs (2016-2026)(US $MN)
Table 17 Global Breast Cancer Drug Market Outlook, By Antimetabolites (2016-2026)(US $MN)
Table 18 Global Breast Cancer Drug Market Outlook, By Anthracyclines (2016-2026)(US $MN)
Table 19 Global Breast Cancer Drug Market Outlook, By Alkylating Agents (2016-2026)(US $MN)
Table 20 Global Breast Cancer Drug Market Outlook, By Neoadjuvant Chemotherapy (2016-2026)(US $MN)
Table 21 Global Breast Cancer Drug Market Outlook, By Adjuvant Chemotherapy (2016-2026)(US $MN)
Table 22 Global Breast Cancer Drug Market Outlook, By Taxanes (2016-2026)(US $MN)
Table 23 Global Breast Cancer Drug Market Outlook, By Advanced Breast Cancer (2016-2026)(US $MN)
Table 24 Global Breast Cancer Drug Market Outlook, By Epothilones (2016-2026)(US $MN)
Table 25 Global Breast Cancer Drug Market Outlook, By Hormone Therapy Drugs (2016-2026)(US $MN)
Table 26 Global Breast Cancer Drug Market Outlook, By Ecstasy and Related Drug (ERD) (2016-2026)(US $MN)
Table 27 Global Breast Cancer Drug Market Outlook, By Selective Estrogen-Receptor Modulators (SERMs) (2016-2026)(US $MN)
Table 28 Global Breast Cancer Drug Market Outlook, By Aromatase Inhibitors (2016-2026)(US $MN)
Table 29 Global Breast Cancer Drug Market Outlook, By Luteinising Hormone-Releasing Hormone (2016-2026)(US $MN)
Table 30 Global Breast Cancer Drug Market Outlook, By Other Hormonal Therapies (2016-2026)(US $MN)
Table 31 Global Breast Cancer Drug Market Outlook, By Distribution Channel (2016-2026)(US $MN)
Table 32 Global Breast Cancer Drug Market Outlook, By Clinics (2016-2026)(US $MN)
Table 33 Global Breast Cancer Drug Market Outlook, By Online Pharmacies (2016-2026)(US $MN)
Table 34 Global Breast Cancer Drug Market Outlook, By Ambulatory Surgical Centers (2016-2026)(US $MN)
Table 35 Global Breast Cancer Drug Market Outlook, By Hospitals (2016-2026)(US $MN)
Table 36 Global Breast Cancer Drug Market Outlook, By Retail Pharmacies (2016-2026)(US $MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[乳がん薬の世界市場展望2017-20276]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆